LEFLUNOMIDE APOTEX leflunomide 20mg tablets blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

leflunomide, Quantity: 20 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

Leflunomide

Pharmaceutical form:

Tablet, uncoated

Composition:

Excipient Ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; lactose

Administration route:

Oral

Units in package:

30 tablets

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

LEFLUNOMIDE APOTEX is indicated for the treatment of: active rheumatoid arthritis; active psoriatic arthritis. GenRx Leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. The combined use of GenRx Leflunomide with other disease modifying antirheumatic drugs (DMARDs) has not been adequately studied (see Precautions).

Product summary:

Visual Identification: White, arc-triangular shaped tablet. Engraved "LE" over "20" on one side and "APO" on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Registered

Authorization date:

2008-07-14